A 3-Year, Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in the Treatment of Patients with Diabetic Macular Edema

Trial Profile

A 3-Year, Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in the Treatment of Patients with Diabetic Macular Edema

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Dexamethasone (Primary) ; Dexamethasone (Primary)
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Acronyms MEAD
  • Sponsors Allergan
  • Most Recent Events

    • 29 Sep 2014 Primary endpoint has been met (Percentage of Patients With a Best Corrected Visual Acuity Improvement of at least 15 Letters From Baseline in the Study Eye at 39 months), according to an Allergan media release.
    • 29 Sep 2014 Results published in an Allergan media release.
    • 18 Aug 2012 Additional trial location (Belgium) added as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top